Patent US4265886A successfully refreshed from Google Patents.
US4265886A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Spiroketalins and their applications
Assignee: Roecar Holdings Netherlands Antilles NV
•
Filing: 1979-07-02
•
Granted: 1981-05-05
•
Expires: 1999-07-02
Abstract
Abstract The present invention provides a pharmaceutical composition, primarily for the treatment of inflammatory conditions, including benign prostata hypertrophy, the composition containing a spiroketalin such as diosgenyl-β-D-glycoside or hecogenyl-β-D-glycoside. A unit dosage form is provided which contains between 0,3 and 0,75 mgm of the spiroketalin.
Inventors
- 👤 Karl H. Pegel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61P; A61P13/00; A61P13/02; A61P15/00; A61P29/00; C; C07; C07J; C07J71/00; C07J71/0005
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
29 words
An anti-inflammatory composition characterized in that it is in the form of a tablet or capsule and includes a pharmaceutically acceptable carrier and a compound of the formula ##STR2##
Claim 2
Dependent Claim
29 words
An anti-inflammatory composition characterized in that it is in the form of a tablet or capsule and includes a pharmaceutically acceptable carrier and a compound of the formula ##STR2##
Claim 3
Dependent Claim
64 words
where: 1. either a double bond starts at C-5 or C-5 carries an alpha hydrogen (5d), 2. Z is a saccharide selected from the group consisting of glucose, maltose, galactose and lactose which may be partially or completely esterified with a pharmaceutically acceptable monocarboxylic acid, 3. R represents either two hydrogens or a ketonic oxygen, in an amount sufficient to cause an anti-inflammatory action.
Claim 4
Dependent Claim
64 words
where: 1. either a double bond starts at C-5 or C-5 carries an alpha hydrogen (5d), 2. Z is a saccharide selected from the group consisting of glucose, maltose, galactose and lactose which may be partially or completely esterified with a pharmaceutically acceptable monocarboxylic acid, 3. R represents either two hydrogens or a ketonic oxygen, in an amount sufficient to cause an anti-inflammatory action.
Claim 5
Dependent Claim
25 words
A composition according to claim 1 characterised in that the compound is chosen from the group consisting of diosgenyl-β-D-glycoside and hecogenyl-β-D-glycoside, and their pharmaceutically-acceptable esters.
Claim 6
Dependent Claim
29 words
A composition according to claim 1 in dosage form characterised in that the compound is present in unit dosage form to the extent of between 0.3 and 0.75 mgm.
Claim 7
Dependent Claim
40 words
An anti-inflammatory composition in the form of a tablet or capsule and including a compound selected from the group consisting of hecogenin and tigogenin glucosides, maltosides and lactosides, and esters thereof in an amount sufficient to cause an antiinflammatory action.
Claim 8
Dependent Claim
40 words
An anti-inflammatory composition in the form of a tablet or capsule and including a compound selected from the group consisting of hecogenin and tigogenin glucosides, maltosides and lactosides, and esters thereof in an amount sufficient to cause an antiinflammatory action.
Claim 9
Dependent Claim
30 words
A composition according to claim 1 wherein the saccharide moiety is selected from the group consisting of β-D-glucoside, β-D-glucoside acetate, β-D-galactoside acetate, β-D-maltoside acetate, β-D-lactoside acetate, β-D-galactoside, β-D-maltoside and β-D-lactoside.
Claim 10
Dependent Claim
24 words
A composition according to claim 5 wherein the compound is selected from the group consisting of hecogenyl, tigogenyl and diosgenyl glucosides, maltosides and lactosides.
Claim 11
Dependent Claim
17 words
A composition according to claim 1 wherein when the saccharide moiety is esterified it is an acetate.
Claim 12
Independent Claim
37 words
A method of treating a disease caused by an inflammatory condition characterized by the administration to the patient a composition including a pharmaceutically acceptable carrier and an anti-inflammatory effective amount of a compound of the formula ##STR3##
Claim 13
Independent Claim
37 words
A method of treating a disease caused by an inflammatory condition characterized by the administration to the patient a composition including a pharmaceutically acceptable carrier and an anti-inflammatory effective amount of a compound of the formula ##STR3##
Claim 14
Dependent Claim
55 words
where: 1. either a double bond starts at C-5 or C-5 carries an alpha hydrogen (5d), 2. Z is a saccharide selected from the group consisting of glucose, maltose, galactose and lactose which may be partially or completely esterified with a pharmaceutically acceptable monocarboxylic acid, 3. R represents either two hydrogens or a ketonic oxygen.
Claim 15
Dependent Claim
55 words
where: 1. either a double bond starts at C-5 or C-5 carries an alpha hydrogen (5d), 2. Z is a saccharide selected from the group consisting of glucose, maltose, galactose and lactose which may be partially or completely esterified with a pharmaceutically acceptable monocarboxylic acid, 3. R represents either two hydrogens or a ketonic oxygen.
Claim 16
Independent Claim
46 words
A method of treating a disease caused by inflammatory condition characterized by the administration to the patient of an anti-inflammatory-effective amount of a composition including a pharmaceutically acceptable carrier and a compound chosen from the group consisting of diosgenyl-β-D-glycoside and hecogenyl-β-D-glycoside and their pharmaceutically acceptable esters.
Claim 17
Independent Claim
46 words
A method of treating a disease caused by inflammatory condition characterized by the administration to the patient of an anti-inflammatory-effective amount of a composition including a pharmaceutically acceptable carrier and a compound chosen from the group consisting of diosgenyl-β-D-glycoside and hecogenyl-β-D-glycoside and their pharmaceutically acceptable esters.
Claim 18
Independent Claim
29 words
A method of treating benign prostate hypertrophy comprising administering to a patient a composition including a pharmaceutically acceptable carrier and an amount of a compound of the formula ##STR4##
Claim 19
Independent Claim
29 words
A method of treating benign prostate hypertrophy comprising administering to a patient a composition including a pharmaceutically acceptable carrier and an amount of a compound of the formula ##STR4##
Claim 20
Dependent Claim
61 words
where: 1. either a double bond starts at C-5 or C-5 carries an alpha hydrogen (5d), 2. Z is a saccharide selected from the group consisting of glucose, maltose, galactose and lactose which may be partially or completely esterified with a pharmaceutically acceptable monocarboxylic acid, 3. R represents either two hydrogens or a ketonic acid effective to treat benign prostate hypertrophy.
Claim 21
Dependent Claim
61 words
where: 1. either a double bond starts at C-5 or C-5 carries an alpha hydrogen (5d), 2. Z is a saccharide selected from the group consisting of glucose, maltose, galactose and lactose which may be partially or completely esterified with a pharmaceutically acceptable monocarboxylic acid, 3. R represents either two hydrogens or a ketonic acid effective to treat benign prostate hypertrophy.
Claim 22
Dependent Claim
17 words
A method according to claim 8 wherein when the saccharide moiety is esterified it is an acetate.
References Cited (Backward Citations)
US2395339A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-05-04 | 1984-11-03 | 1985-05-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-05-04 | 1988-11-03 | 1989-05-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-05-04 | 1992-11-03 | 1993-05-05 | $7700.00 | Window Closed / Lapsed |